Table 2. Demographic and clinical information available for glioblastoma cohort.

Case number	Gender	Age at diagnosis	Primary tumour location	Treatment at primary	IDH1 mutation status	MGMT promoter methylation	PFS (days)	OS (days)	Dexamethasone at surgery (days prior to surgery, dose)		TMZ at recurrent surgery (days prior to surgery)
									Primary	Recurrence
2	M	39	Frontal lobe	RT/TMZ	WT	No	455	462a	No	No	No
3	F	77	Left inferolateral temporal lobe	RT/TMZ	WT	Unknown	938	1036	No	No	No
4	F	45	Left frontal lobe	RT/TMZ	WT	Unknown	398	679	No	No	No
5	M	76	Right frontal lobe	Unknown	WT	Unknown	315	316a	Unknown	Unknown	Unknown
6	M	72	Right temporoparietal lobe	RT/TMZ	WT	Unknown	266	343	No	No	No
7	M	42	Frontal lobe	RT/TMZ	WT	Unknown	374	453	No	No	No
8	F	81	Right temporal lobe	RT/TMZ	WT	Unknown	277	427	Unknown	Unknown	No
9	M	40	Anterior left temporal lobe	RT/TMZ	WT	Unknown	116	410	No	Yes (26 daysb)	Yes (13 days)
10	M	55	Right frontal lobe	None	WT	No	38	177a	No	Yes (9 days, 1 mg)	No
11	M	72	Left temporal lobe	RT/TMZ	WT	Unknown	300	387	No	No	No
12	M	45	Left temporal lobe	RT/TMZ	WT	No	206	468	Unknown	Yes (2 days, 2 mg)	No
13	F	64	Right posterior temporoparietal lobe	RT/TMZ	WT	Unknown	252	919	No	No	No
15	F	65	Posterior right frontal lobe	Unknown	WT	Yes	310	353	Unknown	No	Unknown

Abbreviations: RT: radiation therapy; TMZ: temozolomide; IDH1: isocitrate dehydrogenase 1; WT: wild-type; MGMT: O-6-methylguanine-DNA methyltransferase; PFS: progression-free survival; OS: overall survival. ^aLost to follow-up. ^bStarted at 2 mg and weaned to 0 mg at 26 days prior to surgery.